Peranan Pencitraan Molekuler Kedokteran Nuklir pada Tata Laksana Kanker Prostat
DOI:
https://doi.org/10.55175/cdk.v49i11.321Keywords:
Kanker prostat, kedokteran nuklir, pencitraan molekulerAbstract
Kanker prostat merupakan kanker tersering kedua dan menjadi penyebab kematian kedelapan akibat kanker pada laki-laki di dunia; di Indonesia, kejadian kanker prostat berada pada urutan kelima tersering sebesar 7,4% dari 183.368 kasus baru. Modalitas pencitraan struktural (USG, CT, dan MRI) merupakan pemeriksaan standar klinis sehari-hari, tetapi terbatas untuk staging kanker prostat, restaging pasien dengan kekambuhan biokimia, serta untuk menilai respons terapi. Teknik pencitraan molekuler kedokteran nuklir dapat digunakan pada staging awal, restaging, serta menilai respons terapi kanker prostat. Pencitraan kedokteran nuklir dengan radiotracer 11C-choline, 18F-fluoromethylcholine, 18F-fluciclovine, 68Ga-PSMA, dan 18F-PSMA berperan signifikan dalam tata laksana kanker prostat.
Prostate cancer is the second most frequent cancer and the eighth leading cause of cancer death in men in the world. In Indonesia, it is the fifth most common cancer with 7.4% from 183,368 new cases. Structural imaging modalities (USG, CT, and MRI) are standard routine clinical examinations, but they were limited for cancer staging, restaging in patients with biochemical recurrence, and in assessing therapeutic response. Nuclear imaging with 11C-choline, 18F-fluoromethylcholine, 18F-fluciclovine, 68Ga-PSMA, and 18F-PSMA have significant role in the management of prostate cancer.
Downloads
References
World Health Organization. International Agency for Research on Cancer [Internet]. 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
World Health Organization. International Agency for Research on Cancer. Indonesia [Internet]. 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
EAU-ESTRO-ESUR-SIOG Guidelines on prostate cancer [Internet]. 2017. Available from: http://uroweb.org/guidelines/compilations-of-all-guidelines/.
Wallitt KL, Khan SR, Dubash S, Tam HH, Khan S, Barwick TD. Clinical PET imaging in prostate cancer. Radiographics 2017;37(5):1512-36.
Graham MM. Clinical molecular imaging with radiotracers: Current status. Medical Principles and Practice 2012;21(3):197-208.
Cuccurullo V, Di Stasio GD, Mansi L. Nuclear medicine in prostate cancer: A new era for radiotracers. World J Nuclear Med. 2018;17(2):70.
Jadvar H, Ballas LK, Choyke PL, Fanti S, Gulley JL, Herrmann K, et al. Appropriate use criteria for imaging evaluation of biochemical recurrence of prostate cancer after definitive primary treatment. J Nuclear Med. 2020;61(4):552-62.
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68 Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nuclear Med Mol Imaging. 2017;44(6):1014-24.
Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, et al. 99mTechnetium-based prostate-specific membrane antigen–radioguided surgery in recurrent prostate cancer. Eur Urol. 2019;75(4):659-66.
Jones W, Griffiths K, Barata PC, Paller CJ. PSMA theranostics: Review of the current status of PSMA-targeted imaging and radioligand therapy. Cancer 2020;12(6):1367.
Ghafoor S, Burger IA, Vargas AH. Multimodality imaging of prostate cancer. J Nuclear Med. 2019;60(10):1350-8.
Calabria F, Chiaravalloti A, Cicciò C, Gangemi V, Gullà D, Rocca F, et al. PET/CT with 18F–choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F–choline PET/CT bio-distribution and pitfalls. A southern Italian experience. Nuclear Med Biol. 2017;51:40-54.
Parent EE, Schuster DM. Update on 18F-fluciclovine PET for prostate cancer imaging. J Nuclear Med. 2018;59(5):733-9.
AXUMIN approval letter [Internet]. 2016 May 27. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208054Orig1s000TOC.cfm.
Gusman M, Aminsharifi JA, Peacock JG, Anderson SB, Clemenshaw MN, Banks KP. Review of 18F-fluciclovine PET for detection of recurrent prostate cancer. Radiographics. 2019;39(3):822-41.
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983;43(4):1809-18.
PROSTASCINT approval letter [Internet]. 1996 Oct 28. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/capcyt102896lab.pdf
Gourni E, Henriksen G. Metal-based PSMA radioligands. Molecules 2017;22(4):523.
Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nuclear Med. 2015;56(8):1185-90.
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eu J Nuclear Med Mol Imaging. 2014;41(1):11-20.
Hoffmann MA, Miederer M, Wieler HJ, Ruf C, Jakobs FM, Schreckenberger M. Diagnostic performance of 68Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with 18FEC PET/CT. Oncotarget. 2017;8(67):111073.
Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nuclear Med Mol Imaging. 2017;44(1):92-101.
Witkowska-Patena E, Gizewska A, Dziuk M, Misko J, Budzynska A, Walecka-Mazur A. Head-to-head comparison of 18F-prostate-specific membrane antigen-1007 and 18F-fluorocholine PET/CT in biochemically relapsed prostate cancer. Clin Nuclear Med. 2019;44(12):e629-e33.
Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, et al. Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease. Pract Radiation Oncol. 2018;8(1):28-39.
Nanni C, Schiavina R, Boschi S, Ambrosini V, Pettinato C, Brunocilla E, et al. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nuclear Med Mol Imaging. 2013;40(1):11-7.
Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L, et al. 18F-fluciclovine PET/CT for the detection of prostate cancer relapse: A comparison to 11C-choline PET/CT. Clin Nuclear Med. 2015;40(8):386-91.
Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: A prospective study in 28 patients. Clin Genitourinary Cancer. 2014;12(2):106-10.
Schuster DM, Nieh PT, Jani AB, Amzat R, Bowman FD, Halkar RK, et al. Anti-3-[18F] FACBC positron emission tomography-computerized tomography and 111In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: Results of a prospective clinical trial. J Urol. 2014;191(5):1446-53.
Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. Head-to-head comparison of68Ga-PSMA-11 PET/CT and18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence. 2017. J Nuclear Med. 2018;59(5):789-94.
Pernthaler B, Kulnik R, Gstettner C, Salamon S, Aigner RM, Kvaternik H. A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET/CT. Clin Nuclear Med. 2019;44(10):566-73.
Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nuclear Med. 2020;61(4):527-32.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
